The role of gut microbiome in cancer at ESMOGI24
ESMOGI24 is taking place as an onsite event in Munich, Germany, from 26 to 29 June 2024, as well as online, through a dedicated virtual platform. The congress will be the place to present impactful new data in GI oncology.
Laurence Zitvogel, Researcher at Gustave Roussy Cancer Centre, shared a keynote address on gut onco-microbiome signatures at ESMOGI24. Here are some of the highlights from the session:
“ESMOGI24: Since the development of Colorectal Cancer (CRC) is intertwined with the gut microbiome, lessons learned about the importance of its composition in immune checkpoint inhibitor therapy response could be crucial in tailoring cancer care.
Being able to identify the patients with poor gut microbiota composition provides clinicians with the opportunity to manipulate the microbiome and thereby potentially enhance their subsequent response to immunotherapy.
Read the ESMO Daily Reporter article to explore how advancing Microbiome Research is reshaping CRC treatment.”
“Fascinating lecture from Dr. Laurence Zitvogel on microbiome and cancer and how we need to pay attention to antibiotics, MADCAM1 and TOPOSCORE may have a role in Colorectal Cancer RR with immunotherapy.”
“Modulating microbiome in Gastrointestinal Cancers by Elena Elez at ESMOGI24. Evidence is supportive Bringing this to trials and clinical practice is very challenging. We will need to work with other specialist to become this a reality.”
““All disease begins in the gut”. ESMOGI24 lecture on microbiome regulating immune system by Laurence Zitvogel.”
“New targets in immunotherapy beyond CTL4 and PD(L)1 – Modulating the microbiome to improve results at ESMOGI24.
More than a gut feeling.. Microbiome contributes to carcinogenesis and impacts on treatment. Impact of antibiotics, FMT…”
“Laurence Zitvogel tour de force microbiome. Meta-analysis:
- AB use -60 to +42d C1 PD1;
- surge pathogenic bacteria
- Post AB down-regulation of gut checkpoint MadCAM
- exodus immunosuppressive cells increases Th17 from gut to cancer
- PD1 at this point amplifies exodus/doc/hard place”
For more coverage on ESMOGI24, visit the OncoDaily website.